CYP19A1 and breast cancer: Additional research is needed to fully understand these associations, particularly, the risk of T2D among premenopausal women with breast cancer, and the risk of T2D according to type of endocrine therapy—i.e., tamoxifen therapy or aromatase inhibitors.